Hidradenitis suppurativa: treatment (part 3)


Cite item

Full Text

Abstract

Local and systemic methods are used for the treatment of hidradenitis suppurativa, the choice of which depends on the stage of the disease. For local treatment adapalene, clindamycin, azelaic acid, silver preparations in combination with surgical excision, laser therapy and cryo are used. For systemic treatment antibiotics (clindamycin, rifampicin, erythromycin, amoxicillin with clavulanic acid, minocycline), prednisolone, cytostatics (methotrexate, azathioprine, cyclosporine), retinoids, biologicals (etanercept, efalizumab, adalimumab, infliximab), a non-steroidal anti-inflammatory drugs are used. The aim of therapy is to get anti-inflammatory effect, the removal offollicular occlusion and pain, correction of immune and hormonal status, stimulation of healing of skin defects, improving the quality of life of patients.

About the authors

S. A Masyukova

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

V. V Mordovtseva

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

S. S Zemlyakova

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

E. I Gubanova

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

Inna V. Ilina

Moscow State University of Food Production

Email: Il.inna2012@yandex.ru
MD, PhD, docent Department of Skin and Venereal Diseases with the course of Cosmetology the Medical Institute of Physicians Advanced Training Moscow State University of Food Production Moscow, 125080, Russian Federation

E. G Sanakoeva

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

Z. A Alieva

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

D. V Grebenyuk

Moscow State University of Food Production

Department of skin and venereal diseases with the course of cosmetology the Medical Institute of Physicians Advanced Training Moscow, 125080, Russian Federation

References

  1. Alhusayen R., Shear N.H. Pharmacologic interventions for Hidradenitis suppurativa: what does the evidence say? Am. J. Clin. Dermatol. 2012; 13(5): 283-91.
  2. Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradeitis patients. Dermatol. Online J. 2013; 14(4): 1.
  3. Martin-Ezquerra G., Masferrer E., Masferrer-Niubo M. Use of biological treatments in patients with Hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2015; 29(1): 56-60. doi: 10.1111/jdv.12438.
  4. Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol. Online J. 2013; 19(6): 18558.
  5. Jemec G.B., Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 1998; 39(6): 971-4.
  6. Jemec G.B. Medical treatment of hidradenitis suppurativa. Expert Opin. Pharmacother. 2004; 5(8): 1767-70.
  7. Kagan R.J., Yakuboff K.P., Warner P., Warden G.D. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery. 2005; 138(4): 734-40.
  8. Gener G., Canoui-Poitrine F., Revuz J.E., Faye O., Poli F., Gabison G., et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009; 219(2): 148-54.
  9. von der Werth J.M., Jemec G.B. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol. 2001; 144(4): 809-13.
  10. Корейба К.А., Доброквашин С.В., Демьянов С.Л. Хирургическое лечение хронических свищевых форм гидраденита подмышечных областей. Казанский медицинский журнал. 2010; 91(4): 545-6.
  11. Altunay I.K., Gokdemir G., Kurt A., Kaiaoglu S. Hidradenitis suppurativa and squamous cell carcinoma. Dermatol. Surg. 2002; 28(1): 88-90.
  12. Fadel M.A., Tawfik A.A. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin. Exp. Dermatol. 2015; 40(2): 116-22. doi: 10.1111/ced.12459.
  13. Pagliarello C., Fabrizi G., Feliciani C., Di Nuzzo S. Cryoinsufflation for Hurley stage II Hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided. JAMA Dermatol. 2014; 150(7): 765-6.
  14. Братийчук А.Н., Беслекоев У.С., Заходякин С.И., Миняйлов Н.А. Применение аппарата «Плазон» при лечении больных с гнойной хирургической инфекцией в поликлинике. Военно-медицинский журнал. 2009; 330(3): 72-3.
  15. Белобородова Н.В. Современные возможности антибиотикотерапии в хирургии: инфекции кожи и мягких тканей. Фарматека. 2009; 19: 31-5.
  16. Таха Т.В., Нажмутдинова Д.К. Рациональный выбор антибиотикотерапии при пиодермиях. Русский медицинский журнал. 2008; 16(8): 552-5.
  17. Хачатрян Н.Н., Дизенгоф И.М., Смирнов Г.Г., Лазуткина Л.И., Фесенко Т.А. Особенности антибактериальной терапии хирургических инфекций кожи и мягких тканей. Consilium Medicum. Хирургия. 2011; 31: 34-7.
  18. Самгин М.А., Монахов С.А. Современный взгляд на терапию акне. Российский журнал кожных и венерических болезней. 2003; 5: 59-65.
  19. Join-Lambert O., Coignard H., Jais J.P., Guet-Revillet H., Poiree S., Fraitag S., et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011; 222 (1): 49-58.
  20. Boer J., Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br. J. Dermatol. 2011; 164(1): 170-5.
  21. Boer J., Van Gemert M.J. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J. Am. Acad. Dermatol. 1999; 40(1): 73-6.
  22. Jansen T., Plewig G. What’s new in acne inversa (alias hidradnitis suppurativa)? J. Eur. Acad. Dermatol. 2000; 14(5): 342-3.
  23. Norris J.F., Cunliffe W.J. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin. Exp. Dermatol. 1986; 11(6): 579-83.
  24. van der Zee H.H., van der Woude C.J., Florencia E.F., Prens E.P. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br. J. Dermatol. 2010; 162(1): 195-7.
  25. Grant A., Gonzalez T., Montgomery M.O., Cardenas V., Kerdel F.A. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, doubleblind, placebo-controlled crossover trial. J. Am. Acad. Dermatol. 2010; 62(2): 205-17.
  26. Hunger R.E., Sovy A.M., Hassan A.S., Braathen L.R., Yawalkar N. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br. J. Dermatol. 2008; 158(4): 691-7.
  27. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J. Cutan. Med. Surg. 2009; 13(4): 221-5.
  28. Haslund P., Lee R.A., Jemec G.B. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm. Venereol. 2009; 89(6): 595-600. doi: 10.2340/00015555-0747.
  29. Matusiak L., Bieniek A., Szepietowski J.C. Increased serum tumour necrosis factoralpha in hidradenitis suppurativa patients: is there a basis for treatment with antitumour necrosis factor-alpha agents? Acta Derm. Venereol. 2009; 89(6): 601-3.
  30. Antonucci A., Negosanti M., Negosanti L., Iozzo I., Varotti C. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm. Venereol. 2008; 88(3): 274-5.
  31. Sullivan T.P., Welsh E., Kedel F.A., Burdick A.E., Kirsner R.S. Infliximab for hidradenitis suppurativa. Br. J. Dermatol. 2003; 149(5): 1046-9.
  32. Fardet L. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J. Am. Acad. Dermatol. 2007; 56(4): 624-8.
  33. Mekkes J.R., Bos J.D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br. J. Dermatol. 2008; 158(2): 370-4.
  34. Matusiak L., Bieniek A., Szepietowski J.C. Psychophysical aspects of hidradenitis suppurativa. Acta Derm. Venereol. 2010; 90(3): 264-8.
  35. Lavogiez C., Delaporte E., Darras-Vercambre S., Martin De Lassalle E., Castillo C., Mirabel X., et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010; 220(2): 147-53.
  36. Revuz J. Hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2009; 23(9): 985-98.
  37. Wollina U., Koch A., Heinig B., Kittner T., Nowak A. Acne inversa (Hidradenitis suppurativa): a review with a focus on pathogenesis and treatment. Indian Dermatol. Online J. 2013; 4(1): 2-11.
  38. Wiseman M.C. Hidradenitis suppurativa: a review. Dermatol. Ther. 2004; 17(1): 50-4.
  39. Yazdanyar S., Jemec G.B. Hidradenitis suppurativa: a review of cause and treatment. Curr. Opin. Infect. Dis. 2011; 24(2): 118-23.
  40. Joseph M.A., Jayaseelan E., Ganapathi B., Stephen J. Hidradenitis suppurativa treated with finasteride. J. Dermatol. Treat. 2005; 16(2): 75-8.
  41. Kraft J.N., Searles G.E. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J. Cutan. Med. Surg. 2007; 11(4): 125-31.
  42. Brocard A., Knol A.C., Khammari A., Dreno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007; 214(4): 325-7.
  43. Dufour D.N., Bryld L.E., Jemec G.B. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology. 2010; 220(4): 323-5.
  44. Liedgens H., Hertel N., Gabriel A., Nuijten M., Dakin H., Mitchell S., Nautrup B.P. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. Clin. Drug. Investig. 2008; 28(9): 583-601.
  45. Ho K.Y., Huh B.K., White W.D., Yeh C.C., Miller E.J. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin. J. Pain. 2008; 24(1): 51-5.
  46. Finch P.M., Knudsen L., Drummond P.D. Reduction of allodynia in patients with complex regional pain syndrome: A doubleblind placebo-controlled trial of topical ketamine. Pain. 2009; 146(1-2): 18-25.
  47. Uzaraga I., Gerbis B., Holwerda E., Gillis D., Wai E. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support. Care Cancer. 2012; 20(7): 1515-24.
  48. Tekelioglu U.Y., Apuhan T., Akkaya A., Demirhan A., Yildiz I., Simsek., et al. Comparison of topical tramadol and ketamine in pain treatment after tonsillectomy. Paediatr. Anaesth. 2013; 23(6): 496-501.
  49. Choi S.S., Lee J.K., Suh H.W. Antinociceptive profiles of aspirin and acetaminophen in formalin, substance P and glutamate pain models. Brain. Res. 2001; 921(1-2): 233-9.
  50. Vaithianathan R., Hockey P.M., Moore T.J., Bates D.W. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug. Saf. 2009; 32(4): 335-43.
  51. Chizh B.A., Gohring M., Troster A., Quartey G.K., Schmelz M., Koppert W. The combination of pregabalin with a COX2 inhibitor such as parecoxib was more effective than the pregabalin alone. Br. J. Anaesth. 2007; 98(2): 246-54.
  52. Plested M., Budhia S., Gabriel Z. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review. BMC Neurol. 2010; 10: 116. doi: 10.1186/1471-2377-10-116.
  53. Patorno E., Bohn R.L., Wahl P.M., Avorn J., Patrick A.R., Liu J., Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010; 303(14): 1401-9.
  54. Devulder J., Lambert J., Naeyaert J.M. Gabapentin for pain control in cancer patients’ wound dressing care. J. Pain. Symptom. Manage. 2001; 22(1): 622-6.
  55. Canoui-Poitrine F., Revuz J.E., Wolkenstein P., Viallette C., Gabison G., Pouget F., et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J. Am. Acad. Dermatol. 2009; 61(1): 51-7.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies